Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver

被引:10
|
作者
Godinez-Leiva, Eddison [1 ]
Bril, Fernando [1 ,2 ,3 ]
机构
[1] Univ Alabama Birmingham, Div Endocrinol Diabet & Metab, Birmingham, AL 35233 USA
[2] Univ Florida, Dept Med, Gainesville, FL USA
[3] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35233 USA
关键词
NAFLD; steatohepatitis; NASH; T2DM; insulin resistance; liver; MAGNETIC-RESONANCE ELASTOGRAPHY; HEPATIC TRIGLYCERIDE CONTENT; IMPAIRED INSULIN-CLEARANCE; TYPE-2; DIABETES-MELLITUS; LIFE-STYLE MODIFICATION; CARDIOVASCULAR-DISEASE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BARIATRIC SURGERY; CONTROLLED-TRIAL;
D O I
10.2174/1573402116999201209203534
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) has consolidated as a major public health problem, affecting-25% of the global population. This percentage is significantly higher in the setting of obesity and/or type 2 diabetes. The presence of NAFLD is associated with severe liver complications, such as nonalcoholic steatohepatitis (NASH; i.e., presence of inflammation and necrosis), cirrhosis and hepatocellular carcinoma. However, the majority of these patients die of cardiovascular disease. For this reason, management of this condition requires a multidisciplinary team, where primary care providers are at center stage. However, important misconceptions remain among primary care providers, preventing them from appropriately approach these patients. Nonalcoholic fatty liver disease should be understood as part of a systemic disease characterized for abnormal accumulation of fat in tissues other than the adipose tissue. This, in turn, produces dysfunction of those organs or tissues (process sometimes referred to as lipotoxicity). Therefore, due to the systemic nature of this condition, it should not surprise that NAFLD is closely related to other metabolic conditions. This review will focus on the extrahepatic manifestations of NAFLD and its metabolic and cardiovascular implications. We believe these are the most important issues primary care providers should understand in order to effectively manage these complicated patients. In addition, we have provided a simple and straightforward approach to the diagnosis and treatment of patients with NAFLD and/or NASH. We hope this review will serve as a guide for primary care providers to approach their patients with NAFLD.
引用
收藏
页码:94 / 111
页数:18
相关论文
共 50 条
  • [21] Nonalcoholic fatty liver disease from a primary care perspective
    Clark, Jeanne M.
    Cryer, Donna R. H.
    Morton, Michelle
    Shubrook, Jay H.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1421 - 1433
  • [22] MANAGEMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN A PRIMARY CARE SETTING
    Gips, Julia R.
    Yanek, Lisa
    Wu, Jiajun
    Woreta, Tinsay A.
    Hamilton, James P.
    Clark, Jeanne M.
    HEPATOLOGY, 2023, 78 : S1003 - S1004
  • [23] Beyond the liver: The role of neurotensin in nonalcoholic fatty liver disease
    Barchetta, Ilaria
    JOURNAL OF INTERNAL MEDICINE, 2023, 294 (03) : 245 - 247
  • [24] Psoriasis in liver disease: Associations beyond nonalcoholic fatty liver disease
    Yang, Jason J.
    Nguyen, Kevin A.
    Fleischman, Michael W.
    Aly, Omar
    Cheng, Kyle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 883 - 885
  • [25] Noninvasive Markers of Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease (NAFLD)
    Alkhouri, Naim
    Carter-Kent, Christine A.
    Alisi, Anna
    Feldstein, Ariel E.
    Nobili, Valerio
    GASTROENTEROLOGY, 2010, 138 (05) : S453 - S453
  • [26] Protein glutathionylation increases in liver of patients with nonalcoholic fatty liver disease (nafld)
    Nobili, V.
    Devito, R.
    Comparcola, D.
    Sartorelli, M. R.
    Guidi, R.
    Manco, M.
    Alisi, A.
    Tozzi, G.
    Passarelli, C.
    Gaeta, L.
    Fruhwirth, R.
    Piemonte, F.
    Marcellini, M.
    DIGESTIVE AND LIVER DISEASE, 2007, 39 (10) : A85 - A85
  • [27] CHARACTERISTICS OF THE FATTY ACID COMPOSITION IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Yamada, K.
    Mizukoshi, E.
    Takeshita, Y.
    Arai, K.
    Yamashita, T.
    Sakai, A.
    Kaneko, S.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S505 - S506
  • [28] A decision analysis of the value of liver biopsy in nonalcoholic fatty liver disease (NAFLD)
    Jinks, Jill
    Hillner, Bruce
    Sanyal, Arun
    GASTROENTEROLOGY, 2006, 130 (04) : A824 - A825
  • [29] Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
    Kaswala, Dharmesh H.
    Lai, Michelle
    Afdhal, Nezam H.
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) : 1356 - 1364
  • [30] Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)
    Ajay Duseja
    Naga Chalasani
    Hepatology International, 2013, 7 : 755 - 764